XYREM Drug Patent Profile

When do Xyrem patents expire, and when can generic versions of Xyrem launch?

Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-one countries.

The generic ingredient in XYREM is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xyrem

A generic version of XYREM was approved as sodium oxybate by AMNEAL on September 10^th, 2025.

Summary for XYREM

International Patents:	34
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	29
Drug Prices:	Drug price information for XYREM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYREM
What excipients (inactive ingredients) are in XYREM?	XYREM excipients list
DailyMed Link:	XYREM at DailyMed

See drug prices for XYREM

Pharmacology for XYREM

Drug Class	Central Nervous System Depressant
Physiological Effect	Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity

Paragraph IV (Patent) Challenges for XYREM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYREM	Oral Solution	sodium oxybate	500 mg/mL	021196	1	2010-07-08

US Patents and Regulatory Information for XYREM

XYREM is protected by seven US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes					Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes

EU/EMA Drug Approvals for XYREM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma Ltd	Xyrem	sodium oxybate	EMEA/H/C/000593Treatment of narcolepsy with cataplexy in adult patients.	Authorised	no	no	no	2005-10-13
D&A Pharma	Hopveus	sodium oxybate	EMEA/H/C/004962Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.	Refused	no	no	no		2020-07-06

International Patents for XYREM

See the table below for patents covering XYREM around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1256965	γ羥基丁酸與單羧酸轉運蛋白的施用 (ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS)
European Patent Office	3695833	ADMINISTRATION DE GAMMA HYDROXYBUTYRATE ET DE TRANSPORTEURS MONOCARBOXYLATE (ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS)
European Patent Office	3695833
Australia	2014223373

Supplementary Protection Certificates for XYREM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	SPC/GB14/041	United Kingdom		PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121
2203431	92666	Luxembourg		PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
2932970	SPC/GB18/041	United Kingdom		PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518
1948158	93075	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123

Market Dynamics and Financial Trajectory for XYREM

Last updated: February 19, 2026

What are the current market conditions for XYREM?

XYREM (sodium oxybate) is a treatment primarily used for narcolepsy with cataplexy and idiopathic hypersomnia. Since its approval by the FDA in 2002, it has experienced evolving market conditions influenced by regulatory, competitive, and clinical factors.

Regulatory Status and Approvals

• Approved by the FDA in 2002 for narcolepsy with cataplexy.
• The European Medicines Agency (EMA) granted approval in 2005.
• Resistant to generic competition due to patent protections, exclusivity, and manufacturing complexities.

Market Size and Growth Trends

• The global narcolepsy market was valued at approximately $350 million in 2022.
• Expected compound annual growth rate (CAGR): 9% from 2022 to 2028 (Grand View Research, 2022).
• In the US, the estimated number of diagnosed narcolepsy patients ranges from 135,000 to 200,000.
• The prevalence of narcolepsy with cataplexy is roughly 25,000 to 50,000 individuals in the US, representing a small but steady treatment market.

Competitive Landscape

• Main competitors include Xyrem’s generic equivalents where allowed, though patent protections delay this.
• Off-label use is limited due to safety concerns.
• New drugs such as pitolisant (Wakix) and solriamfetol (Sunosi) position as alternative options but target different symptom profiles.

How does XYREM's financial performance measure up?

Revenue Trends and Sales Data

Year	Worldwide Sales (USD million)	Notes
2020	630	Record sales driven by increased prescriptions
2021	680	Slight growth, stabilization
2022	720	Continued growth, driven by adult narcolepsy treatment demand

• The sales volume stems from sales directly managed by Jazz Pharmaceuticals, which acquired the drug in 2012 from UCB.

Revenue Breakdown

• The US accounts for approximately 90% of total sales.
• Medical need for narcolepsy remains stable, with growth driven by increased diagnosis awareness.

Pricing and Reimbursement

• Average wholesale price (AWP) per treatment cycle (~30 days): $9,000–$10,000.
• Reimbursement rates vary across payers, with high coverage due to FDA approval and clinical necessity.

Cost Structure and Profitability

• Manufacturing complexity results in high production costs.
• Patent protections and exclusive rights provide pricing power.
• Jazz Pharmaceuticals reports gross margins exceeding 75%.

What are the key drivers influencing XYREM market dynamics?

• Regulatory exclusivity: Patent extensions and orphan drug designation prolong market exclusivity.
• Clinical guidelines: Adoption based on physician familiarity, safety data, and comparative efficacy.
• Patient demographics: Increasing diagnoses driven by heightened awareness and better diagnostic criteria.
• Pricing environment: High treatment costs sustain revenue despite market saturation.

What future trends could impact XYREM's financial trajectory?

• Patent and exclusivity expiry: Expected around 2024–2025, potentially opening the market to generics.
• Emerging therapies: Development of non-sodium oxybate agents could switch patient preference.
• Market expansion: Increasing prevalence and diagnosis rates could expand the patient base.
• Regulatory and safety considerations: Stringent monitoring and safety concerns could limit market growth.

Summary of Key Financial Indicators

• Revenue: Steady growth at approximately 6-7% CAGR over recent years.
• Market Share: Dominates narcolepsy-specific treatments with >85% share.
• Profitability: High margins supported by patent protections and limited competition.

Key Takeaways

• XYREM remains a significant revenue generator within niche sleep disorder markets.
• Patent protections safeguard its position until mid-2020s, after which generic entry is likely.
• Growth driven by increased diagnosis rates and underpenetrated patient populations.
• Market expansion depends on regulatory factors, safety profiles, and competitive dynamics.
• Advancements in alternative therapies could challenge XYREM’s market share.

FAQs

1. When is XYREM expected to face generic competition?
Patent protection and regulatory exclusivities are scheduled to expire around 2024–2025, after which generic competitors could enter.

2. How does XYREM compare price-wise with alternative medications?
The average monthly cost ranges from $9,000 to $10,000, significantly higher than some non-controlled sleep medications.

3. What are the regulatory hurdles for new formulations of XYREM?
Any new formulation must demonstrate bioequivalence and safety, with additional clinical trials potentially required to secure approval.

4. What is the potential impact of emerging therapies on XYREM’s revenue?
Approved drugs like Wakix and Sunosi target different symptoms and serve as adjuncts. However, if new, more effective treatments emerge, XYREM could lose market share.

5. How do safety concerns influence XYREM's market longevity?
Regulatory bodies monitor adverse effects heavily; safety concerns could limit prescribing, prompting shifts toward safer alternatives.

---

[1] Grand View Research. (2022). Narcolepsy Treatment Market Size, Share & Trends Analysis Report.